US government warns on patient assistant program drug violations
This article was originally published in SRA
In response to concerns in the US that some charities may be acting as conduits for drug makers to induce prescribing of their higher-priced medicines and other potential abuses involving patient assistant programs (PAPs), the Office of Inspector General for the Department of Health and Human Services has issued a supplemental advisory bulletin, which expands on its 2005 guidance document1-3.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.